Full-Time

Facilities Manager

Capricor Therapeutics

Capricor Therapeutics

201-500 employees

Biotech developing cell- and exosome therapeutics

Compensation Overview

$120k - $140k/yr

San Diego, CA, USA

In Person

Category
Facilities Operations (1)
Requirements
  • High School Diploma/GED or local equivalent required; Bachelor’s degree in a relevant field preferred.
  • 5-8 years of relevant maintenance experience required.
  • 2-4 years of managerial experience in pharmaceuticals, biotech, food processing, high-tech, or other heavily regulated industries required.
  • 2+ years of experience managing facilities under GMP regulatory compliance required.
  • Comprehensive knowledge of maintenance practices for equipment such as boilers, chillers, air handlers, HVAC systems, cooling towers, pure steam generators, Water for Injection systems, autoclaves, heat exchangers, security systems, electrical distribution, fire protection, clean-in-place systems, classified air systems, RODI systems, emergency generators, and fume exhaust systems.
  • Familiarity with pharmaceutical manufacturing equipment, including liquid filling machines, stoppering machines, capping machines, vial washers, and dehydrogenation ovens.
  • Ability to manage multiple responsibilities with strong self-motivation.
  • Capability to work independently and collaboratively in a team-oriented environment.
  • Trained in cGMP operations for pharmaceutical, biotechnology, or medical device manufacturing.
  • Knowledge of aseptic gowning and cleaning techniques.
  • Proficiency in managing after-hours responses and extended shifts to support planned or unplanned events.
  • Strong analytical, problem-solving, and communication skills.
  • Leadership skills to guide and coach teams effectively.
Responsibilities
  • Maintain facilities and process equipment supporting Commercial and Clinical manufacturing, Research and Development, and related services.
  • Manage staff to support 24/7 operations, ensuring safe, reliable, and cost-effective usage.
  • Coach, guide, and direct the facility team, monitoring and assessing performance of maintenance personnel and contractors.
  • Leverage prior GMP knowledge and experience to present to FDA or other regulatory agencies.
  • Collaborate with teams to identify and implement continuous improvement opportunities for systems and processes.
  • Specify and recommend equipment modifications to enhance safety, reliability, and operability.
  • Communicate regularly with customers, partners, and stakeholders to share key developments, opportunities, and risks.
  • Manage operating status and outages for systems, facilities, and utilities to maximize uptime.
  • Develop and implement corrective action plans for facility system repairs, replacements, and modifications.
  • Ensure timely completion of maintenance work orders.
  • Track facilities expenditures and prepare the annual budget.
  • Foster a culture of inclusion, prioritizing safety and injury prevention.
  • Maintain compliance by updating maintenance and operations SOPs for improved scheduling and equipment uptime.
  • Perform additional assigned duties as needed.
Capricor Therapeutics

Capricor Therapeutics

View

Capricor Therapeutics develops cell- and exosome-based therapies to treat serious diseases. Its products use cells or tiny vesicles released by cells to repair heart tissue, Duchenne muscular dystrophy, and COVID-19–related complications, and are advanced through research and clinical trials before potential commercialization. It differentiates itself by focusing on cell- and exosome-based approaches rather than small molecules, pursuing a portfolio aimed at high-need conditions. The company’s goal is to improve patient outcomes by validating these therapies and bringing them to hospitals and healthcare providers, supported by partnerships and grants.

Company Size

201-500

Company Stage

IPO

Headquarters

Beverly Hills, California

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval expected August 22, 2026 enables rapid market entry and revenue generation.
  • Manufacturing facility passed FDA pre-license inspection; capacity scales to 2,500 patients annually.
  • $318 million cash runway funds operations through Q4 2027 post-launch commercialization.

What critics are saying

  • FDA rejects Deramiocel BLA again by August 22, 2026 due to manufacturing deficiencies.
  • Sarepta's Elevidys gene therapy captures 80% DMD market share within 24 months.
  • EVP insider share sales signal management doubts; stock drops 50% pre-approval decision.

What makes Capricor Therapeutics unique

  • First therapy delivering statistically significant upper limb function improvement in DMD.
  • Rare Pediatric Disease Designation qualifies Capricor for valuable Priority Review Voucher.
  • Exclusive US and Japan commercialization partnership with Nippon Shinyaku validates market potential.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Capricor Therapeutics who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Staff Training (not in predefined)

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

2%

2 year growth

-3%
Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $23 Million Registered Direct Offering

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results

HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference Call and Webcast at 4:30…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock

Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics,…...